{"id":"pf-07832837","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentobarbital","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Phenindione","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Esomeprazole","action":"Avoid","effect":"Decreased absorption"},{"drug":"Omeprazole","action":"Avoid","effect":"Decreased absorption"},{"drug":"Lansoprazole","action":"Avoid","effect":"Decreased absorption"},{"drug":"Pantoprazole","action":"Avoid","effect":"Decreased absorption"},{"drug":"Rabeprazole","action":"Avoid","effect":"Decreased absorption"}],"commonSideEffects":[],"contraindications":["No contraindications mentioned in the provided text."],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07832837","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:40:15.365557+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:40:23.029367+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:40:15.389569+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07832837","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:40:23.794066+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4518706/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:40:24.682647+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"PF-07832837 is a compound being studied in a Phase 1 clinical trial to evaluate its tolerability in healthy adults and patients with atopic dermatitis. The study is a randomized, double-blind, placebo-controlled trial comparing PF-07832837 to a placebo.","brandName":"Pf-07832837","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Small molecule","drugClass":"Small molecule","explanation":"","oneSentence":"","technicalDetail":"PF-07832837 is a small molecule drug with a molecular target that is not specified. It works by interacting with a specific biological pathway to produce a therapeutic effect. The exact details of its mechanism of action are not publicly available."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07832837","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07832837","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:32:47.526598+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Lorlatinib","company":"Pfizer","advantage":"Lorlatinib is a more potent inhibitor of ALK and ROS1, with a higher affinity for these targets than PF-02341066 and PF-04880594.","genericName":"Lorlatinib"},{"name":"Crizotinib","company":"Pfizer","advantage":"Crizotinib is a dual inhibitor of ALK and MET, with a similar potency to PF-02341066 but a different spectrum of activity.","genericName":"Crizotinib"},{"name":"Alecensa","company":"Roche","advantage":"Alecensa is a more potent inhibitor of ALK than PF-02341066, with a higher affinity for this target.","genericName":"Alecensa"},{"name":"Xalkori","company":"Pfizer","advantage":"Xalkori is a dual inhibitor of ALK and MET, with a similar potency to PF-02341066 but a different spectrum of activity.","genericName":"Crizotinib"},{"name":"Lorbrena","company":"Pfizer","advantage":"Lorbrena is a more potent inhibitor of ALK and ROS1, with a higher affinity for these targets than PF-02341066 and PF-04880594.","genericName":"Lorlatinib"}],"genericName":"pf-07832837","indications":{"approved":[{"name":"Indication not found"},{"name":"Indication not found"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06564389","phase":"PHASE1","title":"FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-11-05","conditions":"Healthy Participants, Atopic Dermatitis","enrollment":119}],"_emaApprovals":[{"date":"","name":"PF-07832837","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4518706","moleculeType":"Unknown","molecularWeight":"508.49"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4518706"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:32:47.526598+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}